Aprea Therapeutics, Inc. (APRE) stock
Close on Nov 12, 2026Market cap $5.54MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $5.54M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.16
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$14.14M
- EPS, diluted
- -$0.70
- Book value per share
- $0.64
- Diluted shares
- 54M
Trading
- Next earnings
- Mar 15, 2027 (estimated, before the open)
- Previous close
- $0.44
- Open
- $0.45
- Day's range
- $0.44 – $0.45
- Volume
- 149,386
- Average volume (20 days)
- 156,240
- Beta (5 years)
- 1.47
- 52-week range
- $0.41 – $1.49
- RSI (14 days)
- 34.1
- Volatility (1 year)
- 96.5%
- Relative volume
- 0.63×
- WACC
- 12.3%
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | APRE | S&P 500 | Difference | APRE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -25.8% | -2.7% | −23.1 pts | ||
| 3 months | -35.6% | -1.7% | −33.8 pts | ||
| Year to date | -48.4% | +11.9% | −60.3 pts | ||
| 1 year | -65.1% | +12.0% | −77.1 pts | ||
| 3 years | -88.5% | +78.2% | −166.7 pts | -51.4% | +21.2% |
| 5 years | -99.6% | +73.2% | −172.8 pts | -66.1% | +11.6% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Aprea Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Results
- Results
- Results
About Aprea Therapeutics
Pharmaceutical Preparations
Aprea Therapeutics is a clinical-stage precision medicine biopharmaceutical company dedicated to discovering and developing targeted therapies for patients with biomarker-defined cancers. Utilizing the concept of synthetic lethality, the company designs small molecule inhibitors that target specific cancer-related genetic alterations and DNA damage response pathways to selectively destroy cancer cells while sparing healthy tissue. Aprea Therapeutics focuses on advancing its core pipeline programs, which feature its clinical-stage WEE1 kinase inhibitor, APR-1051, and its oral macrocyclic ATR inhibitor, ATRN-119, alongside preclinical candidates such as the DYRK1 inhibitor APR-1602.
Company profile, executives and historyAprea Therapeutics stock: common questions
What is Aprea Therapeutics's stock price?
APRE closed at $0.44 on Nov 12, 2026, down 1.01% on the day. Over the past 52 weeks it traded between $0.41 and $1.49.
What is Aprea Therapeutics's market cap?
Aprea Therapeutics was worth $5.54M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is APRE's P/E ratio?
Aprea Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.70), so it has no meaningful P/E ratio.
Does Aprea Therapeutics pay a dividend?
No. Aprea Therapeutics has not paid a cash dividend over the last twelve months.
When does Aprea Therapeutics report earnings next?
Aprea Therapeutics is expected to report Q4 FY2026 results on Mar 15, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has APRE stock performed over the past year?
Including dividends, APRE returned -65.1% over the past year, against +12.0% for the S&P 500.
How many APRE shares are sold short?
1M shares were sold short at the latest FINRA report, 4.46% of the float, or 2.6 days of average trading volume.
Who are Aprea Therapeutics's competitors?
Companies most similar to Aprea Therapeutics by business, industry and size include PRLD, TNGX, IDYA, ZNTL, ALLR.
See a number that looks wrong?